Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4300 - Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Cytotoxic Therapy

Tumour Site

Prostate Cancer


Zafar Malik


Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284


Z. Malik1, A. Pichler2, G. Di Lorenzo3, U. De Giorgi4, S. Hitier5, E. Ecstein-Fraisse6, A. Ozatilgan7, J. Carles8

Author affiliations

  • 1 The Clatterbridge Cancer Centre, NHS Foundation Trust, CH63 4JY - Wirral/GB
  • 2 Department Of Hematology And Oncology, Regional Hospital Hochsteiermark, Leoben/AT
  • 3 Genitourinary Cancers Section, Aou Feder, University of Naples Federico II, Napoli/IT
  • 4 Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola/IT
  • 5 Biostatistics & Programming, Sanofi, Chilly-Mazarin/FR
  • 6 Medical Evidence Generation, Sanofi, Paris/FR
  • 7 Global Medical Oncology, Sanofi, Cambridge/US
  • 8 Vall D’hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4300


Cabazitaxel is approved for patients with mCRPC, post docetaxel. The CUP (CABAZ_C_05005) and EAP (NCT01254279) provided access to cabazitaxel before commercial availability and assessed real-world safety. CAPRISTANA (CABAZC 06092), a prospective, observational study, evaluated the routine clinical use of cabazitaxel. In this analysis we examined factors associated with cabazitaxel treatment duration in a real-life setting.


Patients ≥18 years of age with mCRPC previously treated with docetaxel, received cabazitaxel 25 mg/m2 intravenously every 3 weeks until disease progression, death, unacceptable toxicity or physician/patient decision. Of note, treatment was capped at 10 cycles in some countries.


The CUP/EAP/CAPRISTANA studies combined included 1,621 patients (CUP/EAP, N = 1,432; CAPRISTANA, N = 189). The median number of cabazitaxel cycles received was 6. Overall, 708 patients (43.7%) received >6 cycles (Table); 211 (13.0%) received >10 cycles. For patients receiving >10 cycles, the median number of cabazitaxel cycles received was 14. Patients receiving more cabazitaxel cycles tended to have better ECOG performance status of 0–1 (Table; P = 0.0017 for ≤6 vs > 6 cycles). In total, 348 patients (21.5%) were ≥75 years of age, of which 40% (n = 139) received >6 cabazitaxel cycles. Further analysis into the patient subgroups and reasons for treatment discontinuation are ongoing.Table: 818P

Cabazitaxel cycles received
≤6 N = 913>6 N = 708
Median age, years (range)68.0 (42–89)68.0 (43–89)
Age, n (%) <65 years 65–75 years ≥75 years271 (29.7) 433 (47.4) 209 (22.9)230 (32.5) 339 (47.9) 139 (19.6)
ECOG PS, n (%) 0–1 2*N = 912 816 (89.5) 96 (10.5)N = 708 665 (93.9) 43 (6.1)
Median cabazitaxel cycles, n (range)4 (1–6)10 (7–49)
Median duration of cabazitaxel exposure, months (range)2.8 (1–6)6.9 (5–35)
Median time from prostate cancer diagnosis, years (range)4.5 (0–22)4.7 (0–20)
Median time from mCRPC diagnosis, years (range)1.7 (0–14)1.8 (0–12)
Median docetaxel cycles at last administration, n (range)7 (1–69)8 (1–58)
Metastatic sites, n (%) Bone Visceral Regional lymph nodesN = 912 829 (90.8) 47 (5.1) 282 (30.9)N = 707 630 (89.0) 23 (3.2) 214 (30.2)
G-CSF during Cycle 1, n (%) Prophylactic Therapeutic BothN = 499 385 (42.2) 69 (7.6) 45 (4.9)N = 380 314 (44.4) 33 (4.7) 33 (4.7)
Pain at baseline (CAPRISTANA study only), n (%) None Moderate SevereN = 86 15 (17.4) 63 (73.3) 8 (9.3)N = 68 18 (26.5) 47 (69.1) 3 (4.4)

Includes one patient with ECOG PS 3 receiving ≤6 cabazitaxel cycles.


Cabazitaxel was well tolerated by patients across these global studies, including elderly patients. Many patients derived benefit from cabazitaxel and went on to receive a greater number of cycles. Further analyses may identify prognostic factors that could indicate which patients are likely to receive >6 cabazitaxel cycles and derive greater benefit. Funding: Sanofi.

Clinical trial identification

Compassionate Use Program (CUP): CABAZ_C_05005. Expanded Access Program (EAP): NCT01254279. CAPRISTANA Registry Study: CABAZC 06092.

Legal entity responsible for the study




Editorial Acknowledgement

Editorial assistance was provided by Danielle Lindley of Meditech Media Ltd, funded by Sanofi.


Z. Malik: Advisory boards, speaker meetings: Sanofi. U. De Giorgi: Consultancy fees: Sanofi, Astellas, Janssen, Bristol-Myers Squibb, Ipsen, Novartis, Pfizer. S. Hitier, E. Ecstein-Fraisse, A. Ozatilgan: Employee: Sanofi. J. Carles: Consultancy, advisory role: Johnson & Johnson, Astellas Pharma, Bayer, Amgen, Pfizer, Bristol-Myers Squibb, Sanofi; Speakers' bureau: Bayer, Johnson & Johnson. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.